🟥 Member Event : 2026 Nurses CE Meeting
2026-05-03 18:30 - 2026-05-05 15:30 (America/New_York)
Date: May 3 – 5, 2026
Location: Chicago, IL

Please note: this application button will redirect you to Cvent, the Alliance’s NEW management registration platform.

Please contact Theresa Parker with any questions regarding this registration at theresa@hemoalliance.org or 727-688-2568.

🟥 Member Event : 2026 Physical Therapists CE Meeting
2026-05-06 18:30 - 2026-05-08 15:30 (America/New_York)
Date: May 6 – 8, 2026
Location: Chicago, IL

Please note: this application button will redirect you to Cvent, the Alliance’s NEW management registration platform.

Please contact Theresa Parker with any questions regarding this registration at theresa@hemoalliance.org or 727-688-2568.

🟥 Member Webinar : Hemophilia Alliance Hosts - A Webinar from Octapharma - Addressing Heavy Menstrual Bleeding in von Willebrand Disease: Clinical Insights and the Role of wilate®
2026-05-12 13:00 - 14:00 (America/New_York)
Date: Tuesday, May 12th, 2026
Time: 1:00pm – 2:00pm ET

WEBINAR TOPIC:
Addressing Heavy Menstrual Bleeding in von Willebrand Disease: Clinical Insights and the Role of wilate®
OBJECTIVES:

Heavy menstrual bleeding (HMB) is one of the most common and underrecognized manifestations of von Willebrand disease (VWD) and represents a significant cause of iron deficiency and iron deficiency anemia in affected women. Chronic blood loss associated with HMB can lead to fatigue, impaired cognitive and physical functioning, reduced quality of life, and increased healthcare utilization. Despite its prevalence, both VWD and iron deficiency related to HMB are frequently underdiagnosed and undertreated.
This webinar will provide a focused clinical overview of HMB in the context of VWD, emphasizing the interconnected relationship between abnormal bleeding and iron deficiency. Participants will review the burden of disease, diagnostic considerations, and treatment goals aimed at controlling bleeding while addressing its systemic consequences. The program will also highlight Wilate®, a VWF/FVIII concentrate, including its clinical profile, supporting evidence, and practical application in the management of HMB associated with VWD. Finally, the webinar will explore Wilate’s clinical and therapeutic value proposition, with an emphasis on optimizing outcomes and improving quality of life for women living with VWD-related HMB.

AUDIENCE:
All HTC Staff.
SPEAKER:

Claudio Sandoval, MD – Senior Director, Scientific and Medical Affairs – Hematology Octapharma USA
Claudio Sandoval is the Director of Scientific & Medical Affairs at Octapharma. Before his current role he was a pediatric hematologist-oncologist for 30 years caring for children with bleeding disorders, cancer, sickle cell disease, and other maladies. Claudio graduated from New York Medical College and trained at Schneider Children’s Hospital in New Hyde Park, NY and St. Jude Children’s Research Hospital in Memphis, TN.

🟥 Member Webinar : Hemophilia Alliance Hosts - An Update on Takeda’s Transformation, Supply Status, and Hemophilia A Treatments
2026-07-22 13:00 - 14:00 (America/New_York)
Date: Wednesday, July 22nd, 2026
Time: 1:00pm – 2:00pm ET

WEBINAR TOPIC:
An Update on Takeda’s Transformation, Supply Status, and Hemophilia A Treatments
OBJECTIVES:

To familiarize audiences with Takeda transformation update
To share reminder on the HEMOFIL® M & RECOMBINATE® supply status
To share HCP presentation focusing on the immunogenicity results of the ADYNOVATE phase 3 trial in previously untreated patients (PUPs) and attributes of ADVATE for previously treated patients (PTPs).

AUDIENCE:
All HTC Staff
SPEAKERS:
Dr. Jonathan Roberts is the Associate Medical Director and Associate Research Director at the Bleeding and Clotting Disorders Institute in Peoria, IL. He also serves as an Associate Professor of Pediatrics and Medicine at the University of Illinois College of Medicine in Peoria, IL.
Dr. Roberts’ research focuses on developing novel laboratory assays to improve the diagnosis of von Willebrand Disease (VWD) and enhancing individualized clinical management of hemophilia, VWD, and other rare bleeding disorders. He has received numerous young investigator research awards and has authored over 100 peer-reviewed research publications and abstracts. His work includes lead and senior author publications in prominent journals such as Blood, the Journal of Thrombosis and Haemostasias, and the New England Journal of Medicine. He has also secured grant funding from organizations such as the National Bleeding Disorders Foundation, the World Federation of Hemophilia, and the National Institutes of Health.

Carley Riehle has been with Takeda for nearly nine years and has built her career around supporting the bleeding disorder community. She began in the field, calling on HTCs, hospitals, and chapters before leading a team of field members, where she developed a deep appreciation for the strength and resilience of the community. She later transitioned to Takeda’s Payer Team, where she focused on creating and protecting access for patients on Takeda therapies. Most recently, Carley was promoted to National Director of Specialty Pharmacy, where she partners with national specialty pharmacies and the Hemophilia Alliance to strengthen Takeda’s relationships, support their members, and ultimately improve access for patients. She is passionate about building trusted partnerships and advancing meaningful support for the bleeding disorder community.

Natalie Wu, Head of Takeda’s US Hematology and Transplant Franchise is biopharmaceutical leader with over 25 years of diverse US and Global experience across Rare Diseases, Oncology, Diabetes, and Neuroscience. Natalie is passionate about building deep connections with the patient communities we serve and the healthcare and advocacy teams who work tirelessly to support patients in their quest for better health. She challenges the status quo to drive meaningful impact where unmet needs and heath inequities remain.

Nicole Loguidice, MBA is Director, Foundational Therapeutics Platform Access Operations at Takeda. With more than eight years of experience in patient access, she has led operations across Hematology, Rare Disease, Endocrinology, and Transplant programs. Nicole is passionate about developing patient-centered access solutions, fostering cross-functional collaboration, and advancing programs that support patients’ access to the therapies they need.

🟥 Member Webinar : Hemophilia Alliance Presents - A Webinar on Planning for Medicaid Work Requirements
2026-07-30 14:00 - 15:00 (America/New_York)

🟥 Member Webinar : New HANS PBM Agreement Opportunities
2026-08-26 13:00 - 14:00 (America/New_York)

🟥 Member Event : 2026 Fall Members Meeting & Hill Day
2026-09-27 18:30 - 2026-09-29 17:30 (America/New_York)
Date: September 27 – 29, 2026
Location: Washington, DC
Please note: this button will redirect you to Cvent, the Alliance’s NEW management registration platform.

Please contact Theresa Parker with any questions regarding this registration at theresa@hemoalliance.org or 727-688-2568.

🟥 Member Event : 2027 MPBA Meeting
2027-01-24 18:30 - 2027-01-26 14:00 (America/Phoenix)
Date: January 24 – 26, 2027
Location: Salt Lake City, UT
Please note: this button will redirect you to Cvent, the Alliance’s NEW management registration platform.

Please contact Theresa Parker with any questions regarding this registration at theresa@hemoalliance.org or 727-688-2568.
